Tezos had a $200 million ICO. Then the lawsuits started. Now a cofounder tells her side.
When it burst on the scene with a $232 million initial coin offering last year, Tezos turned heads for more than its eye-popping valuation. The company promised to bring order to the chaos that surrounded networks like Bitcoin, Ethereum, and others by establishing a way to vote on upgrades to a blockchain network. If it worked, it could resolve one of the thorniest issues in the world of cryptocurrencies.
It hasn’t quite gone to plan. Even as cofounder Kathleen Breitman took the stage today at MIT Technology Review’s Business of Blockchain conference, Tezos was beset by allegations of fraud. But Breitman, whose lawyer was in the audience, appeared undaunted. Even as she marveled that Bitcoin was “extraordinarily resilient” and called it the Coca-Cola of the cryptocurrency world, she asserted that she still would like Tezos to become the Pepsi.
Such determination will be needed. Cryptocurrencies and the larger blockchain community now face a defining moment in their evolution. Global financial regulators have taken notice, and rumors are swirling that cryptocurrencies could soon be subject to the same laws as any stock, bond, or other security.
For her part, Breitman was adamant. Batting away tough questions about what such regulation might mean for her company, she insisted that the future for Tezos is bright—even while she offered little in terms of what it plans to do next.
Correction: The initial version of this article mistakenly referred to Breitman as Tezos's CEO. She is a cofounder.
The inside story of how ChatGPT was built from the people who made it
Exclusive conversations that take us behind the scenes of a cultural phenomenon.
How Rust went from a side project to the world’s most-loved programming language
For decades, coders wrote critical systems in C and C++. Now they turn to Rust.
Design thinking was supposed to fix the world. Where did it go wrong?
An approach that promised to democratize design may have done the opposite.
Sam Altman invested $180 million into a company trying to delay death
Can anti-aging breakthroughs add 10 healthy years to the human life span? The CEO of OpenAI is paying to find out.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.